White Paper by
Enter your details to receive the free white paper
Nine out of 10 clinical trials worldwide can’t recruit enough people within their target timeframes. What if researchers didn’t need to recruit a control group at all and could offer the experimental treatment to everyone in the study?
Download this white paper, in partnership with MIT Technology Review, to learn how Celsion, a biotechnology company developing next-generation chemotherapy and immunotherapy agents, leverages Medidata’s detailed information from 23,000+ trials and 7 million patients to create “external control arms” and speed up the clinical trial process.